Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT02986581
Recruiting Observational

Prospective Cohort Study of Rapid Response Team

NCT02986581 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Hospital
Phase
Observational
Started
2016-11
Last updated
2021-06-30

Condition(s) studied

Hospital Medical Emergency TeamMedicine, EmergencyHospital Rapid Response Team

Study summary

The purpose of this study is to collect data of rapid response team activated patients prospectively

Eligibility

Sex
ALL
Min age
15 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- Patients admitted to general ward in Seoul National University Bundang Hospital and monitored by in-hospital rapid response system. Exclusion Criteria: * patients admitted to pediatric wards * patients in emergency room, intensive care unit, and operating room

Primary outcome measure(s)

  • mortality or ICU admission of rapid response team activated patient — an average of 1 year
  • incidence of preventable cardiac arrest — an average of 1 year

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Bundang Hospital Seongnam-si South Korea Recruiting

More Seoul National University Hospital trials in South Korea

Lung Cancer Surgery in Sarcopenia Patients With Old Age Active, not recruiting
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION) Recruiting
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis Recruiting
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Recruiting
Reduction of Remifentanil-related Complications Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02986581 on ClinicalTrials.gov ↗ ← All trials in South Korea